Nonstimulant ADHD Medication Options
The FDA-approved nonstimulant medications for ADHD are atomoxetine (Strattera), guanfacine extended-release (Intuniv), clonidine extended-release (Kapvay), and viloxazine extended-release, with atomoxetine being the most extensively studied and recommended as the primary second-line option when stimulants fail or are contraindicated 1, 2.
Primary Nonstimulant Options
Atomoxetine (First-Choice Nonstimulant)
Atomoxetine is a selective norepinephrine reuptake inhibitor approved for children, adolescents, and adults with ADHD 2.
Dosing Regimens:
- Children and Adolescents: Start at approximately 0.5 mg/kg/day, titrate to target dose of 1.2 mg/kg/day, with maximum of 1.4 mg/kg/day or 100 mg/day (whichever is lower) 2
- Adults: Similar weight-based approach applies 2
- Available as capsules: 10,18,25,40,60,80, or 100 mg, plus oral solution (4 mg/ml) 2
- Can be dosed once daily or split into two divided doses 3
Key Clinical Characteristics:
- Onset of action: 6-12 weeks for full effect 2
- Duration: Provides "around-the-clock" symptom control 2
- Metabolism: CYP2D6 pathway—approximately 7% of patients are poor metabolizers with higher plasma levels and increased adverse effects 2
- Drug interactions: SSRIs (particularly paroxetine) can elevate atomoxetine levels 2
Critical Safety Warnings:
- Black box warning for suicidal ideation in children and adolescents—monitor closely during first months of treatment and dose changes 2
- This risk was NOT observed in adult trials 2
- Monitor for cardiovascular effects, emergent psychotic/manic symptoms, aggressive behavior, and priapism 2
Common Adverse Effects:
- Children/adolescents: Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence 2
- Adults: Dry mouth, insomnia, nausea, decreased appetite, constipation, urinary retention, sexual dysfunction (2%), decreased libido 3
- Discontinuation rate: 3.5% (vs 1.4% placebo), dose-dependent above 1.5 mg/kg/day 4
Alpha-2 Adrenergic Agonists
Guanfacine extended-release and clonidine extended-release work through alpha-2 receptor agonism in the prefrontal cortex, enhancing noradrenergic neurotransmission 2.
Dosing and Administration:
- Guanfacine ER: Titrate up to 4 mg/day in children and adolescents 5
- Clonidine ER: Requires twice-daily dosing (unlike guanfacine); transdermal patch available 2
- Onset: 2-4 weeks until effects observed 2
Clinical Profile:
- Provide "around-the-clock" effects 2
- Smaller effect size compared to stimulants 2
- Particularly useful for comorbid sleep disorders, tic/Tourette's disorder, disruptive behavior disorders 2
- Can augment stimulant treatment 2
Adverse Effects:
- Most common: Somnolence/sedation (administer in evening to minimize daytime sedation) 2
- Fatigue, hypotension, irritability 2
- Monitor pulse and blood pressure 2
Viloxazine Extended-Release
A newer norepinephrine reuptake inhibitor approved for ADHD 6, 7.
- Provides an additional nonstimulant option with similar mechanism to atomoxetine
- Recommended as a second-line nonstimulant option 7
Clinical Decision Algorithm
When to Use Nonstimulants as First-Line:
- Active substance use disorder or high diversion risk 2
- Comorbid anxiety disorders 3
- Comorbid tic disorder or Tourette's syndrome 2, 3
- Comorbid sleep disorders (particularly alpha-2 agonists) 2
- Patient/family preference to avoid controlled substances 2, 3
- Significant cardiovascular concerns with stimulants
When to Switch to Nonstimulants:
- Inadequate response to adequate stimulant trial (proper dose and duration) 2
- Intolerable stimulant adverse effects
- Need for evening/nighttime symptom control 2
Choosing Between Nonstimulants:
Start with atomoxetine as it has the most robust evidence base and is approved as first-line in some countries 2, 8. Consider alpha-2 agonists when:
- Prominent hyperactivity/impulsivity (over inattention)
- Comorbid sleep problems
- Comorbid tics
- Somnolence is acceptable or desired
Critical Pitfalls to Avoid
Expecting immediate response: Atomoxetine requires 6-12 weeks for full effect; alpha-2 agonists need 2-4 weeks 2. Do not prematurely discontinue.
Underdosing atomoxetine: Must titrate to 1.2-1.4 mg/kg/day for optimal effect 2. Therapeutic inertia leads to suboptimal outcomes 5.
Ignoring CYP2D6 interactions: Patients on paroxetine or other CYP2D6 inhibitors will have significantly elevated atomoxetine levels 2.
Missing suicidality monitoring in youth: The black box warning is real—establish monitoring protocols during initiation and dose changes 2.
Abrupt discontinuation of alpha-2 agonists: Can cause rebound hypertension, particularly with clonidine.
Using clonidine immediate-release instead of extended-release: The ER formulations are FDA-approved for ADHD; immediate-release is not 1.
Comparative Efficacy
Nonstimulants have smaller effect sizes than stimulants 2, 3. Atomoxetine is less effective than extended-release methylphenidate (OROS) and extended-release mixed amphetamine salts, but comparable to immediate-release methylphenidate 3. However, individual response is unpredictable—some patients respond optimally to nonstimulants despite lower average effect sizes 9.
Recent dose-effect analysis shows guanfacine efficacy plateaus at 4 mg/day in youth, with no additional benefit at higher doses 5.
Augmentation Strategy
Nonstimulants can be combined with stimulants for patients with partial stimulant response 2, 7. This is particularly useful when:
- Stimulants provide insufficient duration of coverage
- Residual symptoms persist despite optimized stimulant dosing
- Comorbid conditions require additional pharmacological management